![\"\"](\"https:\/\/mma.prnasia.com\/media2\/821373\/I_MAB_Logo.jpg?p=medium600\" "\\"logo\\""){kind=logo}
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n- \n
- Recently announced agreement to divest assets and business operations in China<\/span> marks an important milestone for the Company; the transaction is expected to close by the end of March 2024<\/span><\/i><\/li>\n
- Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors for patients with newly diagnosed NSCLC in 1H 2024<\/i><\/li>\n
- First patient dosed in an ongoing, triplet combination, dose escalation study of givastomig (CLDN18.2×4-1BB bispecific antibody) in 1Q 2024<\/i><\/li>\n
- RMB2.3 billion<\/span> (US$321.8 million<\/span>) in cash and cash equivalents, and short-term investments as of December 31, 2023<\/span><\/i><\/li>\n<\/ul>\n
ROCKVILLE, Md.<\/span>, March 15, 2024 \/PRNewswire\/ — I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023<\/span>, and highlighted recent business updates.<\/span><\/p>\n
\n<\/p><\/div>\n"2023 was a transitional year for I-Mab and we were pleased to report encouraging clinical results in our two lead global assets in oncology, uliledlimab and givastomig. As we prepare for the closing of the strategic divestiture, we look forward to providing investors with a road map to value creation and believe that our differentiated clinical assets, uliledlimab, givastomig, and ragistomig will achieve critical milestones and trial initiations this year," said Raj Kannan, Director and Chief Executive Officer of I-Mab.<\/p>\n
Pipeline Overview and Upcoming Milestones: <\/b><\/p>\n
Uliledlimab: Phase 2, with a focus on non-small cell lung cancer (NSCLC)<\/b><\/p>\n
Uliledlimab is designed to target CD73 and promote stronger activation of the patient’s immune system against cancer cells. Uliledlimab is potentially differentiated from other products in development due to its non-competitive binding with adenosine monophosphate and the potential for complete inhibition of CD73’s immune dampening function. Encouraging results from a Phase 2 study of uliledlimab in combination with toripalimab, presented at the American Society for Clinical Oncology (ASCO 2023) in patients with advanced NSCLC, provided compelling support for further development of uliledlimab. In particular, the subset of patients with both high CD73 expression and PD-L1 TPS><\/u>1% showed an impressive 63% overall response rate. Additionally, enrollment of patients with treatment resistant ovarian cancer has been completed, and ongoing efforts will be streamlined to focus on expediting NSCLC development.<\/p>\n
- \n
- Upon the receipt of the investigational new drug (IND) approval, the Company plans to initiate the triplet study for uliledlimab in combination with chemotherapy and checkpoint inhibitors in newly diagnosed patients with advanced NSCLC in the second half of 2024.<\/li>\n<\/ul>\n
Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Phase 1b<\/span>, with a focus on gastric cancer and esophageal adenocarcinoma <\/b><\/p>\n
Givastomig was designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Phase 1 monotherapy data presented at the European Society of Medical Oncology (ESMO 2023) showed encouraging objective responses in patients with gastric cancer and esophageal adenocarcinoma whose tumors progressed or recurred after prior standard treatments, including those with low levels of Claudin 18.2 expression. This program is being jointly developed with ABL Bio. I-Mab owns 50% of the global rights of givastomig. <\/p>\n
- \n
- The enrollment of patients from the U.S. and China<\/span> with newly diagnosed (frontline treatment) gastric and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor began in the first quarter of 2024.<\/li>\n<\/ul>\n
Ragistomig (PD-L1 x 4-1BB bispecific antibody): Phase 1 dose escalation, with a focus on solid tumors<\/b><\/p>\n
Ragistomig was designed as a bispecific antibody to address PD-L1 resistant tumors, differentiated by the conditional activation of 4-1BB’s pro-immune stimulation when it binds to its PD-L1 target. Early observations reported by our development partner, ABL Bio, showed promising objective responses in patients with various solid tumors whose tumors progressed or recurred after prior standard treatments, including in patients with relapsed or refractory cancer after prior PD-L1 inhibitors. These early signs of efficacy are encouraging, and enrollment in the Phase 1 study continues. This program is being jointly developed with ABL Bio. I-Mab owns 50% of the global rights of ragistomig (TJ-L14B\/ABL503).<\/p>\n
- \n
- Top-line Phase 1 dose escalation and dose expansion results are expected to be presented at a major medical conference in the first half of 2024.<\/li>\n<\/ul>\n
Impact of Strategic Transaction on Pipeline<\/b><\/p>\n
The agreement to divest assets and business operations in China<\/span>, previously announced in a press release on February 7, 2024<\/span>, is expected to be completed by the end of March 2024<\/span>. Upon the closing of the transaction, the Greater China<\/span> rights for assets including eftansomatropin alfa, felzartamab, uliledlimab, and givastomig will be transferred to I-Mab Biopharma (Hangzhou<\/span>) Co., Ltd., an unconsolidated affiliate (the "Hangzhou Company<\/b>"). I-Mab will no longer bear future development costs of these divested assets in China<\/span> and may receive an aggregate consideration of the RMB equivalent of up to US$80 million<\/span>, contingent on the Hangzhou Company group’s achievement of certain future regulatory and sales-based milestone events relating to these divested assets in China<\/span>. The transaction, if closed, will also extinguish existing repurchase obligations owed by a wholly-owned subsidiary of the Company in the amount of approximately US$183 million<\/span>.<\/p>\n
As a result of the closing of the transaction, the Company will cease consolidation of the divested entities, assets, and businesses as well as their corresponding financial results. The Company’s financial condition and results of operations will be materially affected and the Company’s historical results will not be indicative of future financial condition or results of operations.<\/p>\n
Full-Year 2023 Financial Results<\/b><\/p>\n
Cash Position<\/b><\/p>\n
As of December 31, 2023<\/span>, the Company had cash, cash equivalents, and short-term investments of RMB2.3 billion<\/span> (US$321.8 million<\/span>), compared with RMB3.5 billion<\/span> as of December 31, 2022<\/span>.<\/p>\n
Share Buyback<\/b><\/p>\n
In August 2023<\/span>, the Board of Directors of the Company authorized a new share repurchase program under which the Company may repurchase up to US$40 million<\/span> of American Depository Shares ("ADSs"), each ten ADSs representing 23 ordinary shares of the Company, or ordinary shares in aggregate over a 12-month period. During the period ended December 31, 2023<\/span>, the Company repurchased US$8.6 million<\/span> of its ADSs, equating to 4,633,386 ADSs or 10,656,794 ordinary shares. As of December 31, 2023<\/span>, the Company had issued and outstanding ordinary shares of 185,613,662, representing the equivalent of 80,701,592 ADSs assuming the conversion of all ordinary shares into ADSs.<\/p>\n
Net Revenues<\/b><\/p>\n
Total net revenues for the full year of 2023 were RMB27.6 million<\/span> (US$3.9 million<\/span>), compared with RMB-221.6 million<\/span> (US$-32.1 million<\/span>) for the full year of 2022. Total net revenues in 2023 consisted of revenues recognized in connection with the strategic collaboration with AbbVie Inc. (AbbVie) and revenues generated from the supply of investigational products to AbbVie and Human Immunology Biosciences, Inc. The negative figure for net revenue in 2022 was primarily due to a one-time, non-cash accounting treatment of US$-48.0 million<\/span> (equivalent to RMB-314.2 million<\/span>) recorded in the second half of 2022 following the amendment to the original license and collaboration agreement with AbbVie in August 2022<\/span>. This amendment led to a reduced probability of achieving a key milestone that was included in the consideration of revenue recognition in prior years.<\/p>\n
Research & Development Expenses<\/b><\/p>\n
Research and development expenses for the full year of 2023 were RMB810.6 million<\/span> (US$114.2 million<\/span>), compared with RMB904.9 million<\/span> (US$131.2 million<\/span>) for the full year of 2022. The decrease was primarily due to reduced payroll expenses related to headcount optimization as a result of asset prioritization and reduced share-based compensation expenses. Share-based compensation expense was RMB66.8 million<\/span> (US$9.4 million<\/span>) for the full year of 2023, compared with RMB117.9 million<\/span> (US$17.1 million<\/span>) for the full year of 2022.<\/p>\n
Administrative Expenses<\/b><\/p>\n
Administrative expenses for the full year of 2023 were RMB453.0 million<\/span> (US$63.8 million<\/span>), compared with RMB815.8 million<\/span> (US$118.3 million<\/span>) for the full year of 2022. The decrease was primarily due to reduced payroll expenses related to decreased headcount as a result of resource optimization and reduced share-based compensation expenses for management personnel, reduced expenses for professional services, and reduced legal expenses in relation to the disputes with Tracon Pharmaceuticals, Inc. of RMB95.5 million<\/span> (US$13.5 million<\/span>). Share-based compensation expense was RMB126.2 million<\/span> (US$17.8 million<\/span>) for the full year of 2023, compared with RMB239.3 million<\/span> (US$34.7 million<\/span>) for the full year of 2022.<\/p>\n
Other Expenses, Net<\/b><\/p>\n
Net other expenses for the full year of 2023 were RMB38.1 million<\/span> (US$5<\/span>.4 million), compared with RMB126.6 million<\/span> (US$18.4 million<\/span>) for the full year of 2022. The change was primarily driven by unrealized exchange rate losses due to the significant fluctuation in the exchange rate of the Renminbi against the U.S. dollar in 2022.<\/p>\n
Equity in Loss of Affiliates<\/b><\/p>\n
Equity in loss of affiliates for the full year of 2023 was RMB80.0 million<\/span> (US$11.3 million<\/span>), compared with RMB437.5 million<\/span> (US$63.4 million<\/span>) for the full year of 2022. The loss was mainly recognized in relation to the operating loss of the Company’s investee, I-Mab Biopharma (Hangzhou<\/span>) Co., Ltd.<\/p>\n
Impairment <\/b>of<\/b> Goodwill<\/b><\/p>\n
For the full year of 2023, the Company recognized an impairment of goodwill of RMB162.6 million<\/span> (US$22.9 million<\/span>). The goodwill impairment resulted from the Company’s annual impairment analysis, and reflects the continued disconnect between I-Mab’s anticipated future performance and present uncertainty reflected in its market valuation.<\/p>\n
Net Loss<\/b><\/p>\n
Net loss for the full year of 2023 was RMB1,465<\/span>.7 million (US$206.4 million<\/span>), compared with RMB2,507.3 million<\/span> (US$363.5 million<\/span>) for the year 2022. Net loss per share attributable to ordinary shareholders for the full year of 2023 was RMB7<\/span>.19 (US$1.01), compared with RMB13.21<\/span> (US$1.92)<\/span> for the full year of 2022. Net loss per ADS attributable to ordinary shareholders for the full year of 2023 was RMB16.54<\/span> (US$2.33)<\/span>, compared with RMB30.38<\/span> (US$4.41)<\/span> for the full year of 2022.<\/p>\n
Non-GAAP Net Loss<\/b><\/p>\n
Non-GAAP adjusted net loss, which excludes share-based compensation expenses and impairment of goodwill, for the full year of 2023 was RMB1,105.3 million<\/span> (US$155<\/span>.7 million), compared with RMB2,136.3 million<\/span> (US$309.7 million<\/span>) for the full year of 2022. Non-GAAP adjusted net loss per share attributable to ordinary shareholders for the full year of 2023 was RMB5<\/span>.42 (US$0.76), compared with RMB11.26<\/span> (US$1.63)<\/span> for the full year of 2022. Non-GAAP adjusted net loss per ADS attributable to ordinary shareholders for the full year of 2023 was RMB12<\/span>.47 (US$1.76), compared with RMB25.90<\/span> (US$3.75)<\/span> for the full year of 2022.<\/p>\n
Use of Non-GAAP Financial Measures<\/b><\/p>\n
To supplement its consolidated financial statements, which are presented in accordance with U.S. GAAP, the Company uses adjusted net income (loss) as a non-GAAP financial measure. Adjusted net income (loss) represents net income (loss) before share-based compensation and impairment of goodwill. The Company’s management believes that adjusted net income (loss) facilitates understanding of operating results and provides management with a better capability to plan and forecast future periods. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.<\/p>\n
Non-GAAP information is not prepared in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for GAAP results. A limitation of using adjusted net income (loss) is that adjusted net income (loss) excludes share-based compensation expense and impairment of goodwill that has been and may continue to be incurred in the future.<\/p>\n
Exchange Rate Information<\/b><\/p>\n
This announcement contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars of the financial results for the year of 2023 are made at a rate of RMB7.0999 to US$1.00, the rate in effect as of December 29, 2023, published by the Federal Reserve Board. All translations from Renminbi to U.S. dollars of the financial results for the year of 2022 are made at a rate of RMB6.8972 to US$1.00, the rate in effect as of December 30, 2022 published by the Federal Reserve Board.<\/p>\n
<\/p>\n
<\/p>\n
\n\n\n
\n \n I-Mab<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Consolidated Balance Sheets<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n (All amounts in thousands, except for share and per share data, unless otherwise noted)<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n <\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n \n As of December 31,<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n As of December 31,<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n <\/td>\n <\/td>\n \n 2022<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 2023<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n <\/td>\n <\/td>\n \n RMB<\/b><\/span><\/p>\n<\/td>\n
\n US$<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n RMB<\/b><\/span><\/p>\n<\/td>\n
\n US$ <\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n <\/td>\n <\/td>\n \n (Unaudited)<\/i><\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n (Unaudited)<\/i><\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n \n Current assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n \n Cash and cash equivalents<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 3,214,005<\/span><\/p>\n<\/td>\n
\n 465,987<\/span><\/p>\n<\/td>\n
<\/td>\n \n 2,141,445<\/span><\/p>\n<\/td>\n
\n 301,616<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Short-term restricted cash<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 96,764<\/span><\/p>\n<\/td>\n
\n 14,029<\/span><\/p>\n<\/td>\n
<\/td>\n \n –<\/span><\/p>\n<\/td>\n
\n –<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Short-term investments<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 235,429<\/span><\/p>\n<\/td>\n
\n 34,134<\/span><\/p>\n<\/td>\n
<\/td>\n \n 143,221<\/span><\/p>\n<\/td>\n
\n 20,172<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Prepayments and other receivables<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 80,278<\/span><\/p>\n<\/td>\n
\n 11,639<\/span><\/p>\n<\/td>\n
<\/td>\n \n 52,003<\/span><\/p>\n<\/td>\n
\n 7,325<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Total current assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 3,626,476<\/b><\/span><\/p>\n<\/td>\n
\n 525,789<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 2,336,669<\/b><\/span><\/p>\n<\/td>\n
\n 329,113<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Long-term restricted cash<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n –<\/span><\/p>\n<\/td>\n
\n –<\/span><\/p>\n<\/td>\n
<\/td>\n \n 58,913<\/span><\/p>\n<\/td>\n
\n 8,298<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Property, equipment and software<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 60,841<\/span><\/p>\n<\/td>\n
\n 8,821<\/span><\/p>\n<\/td>\n
<\/td>\n \n 36,511<\/span><\/p>\n<\/td>\n
\n 5,142<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Operating lease right-of-use assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 63,125<\/span><\/p>\n<\/td>\n
\n 9,152<\/span><\/p>\n<\/td>\n
<\/td>\n \n 46,400<\/span><\/p>\n<\/td>\n
\n 6,535<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Intangible assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 118,888<\/span><\/p>\n<\/td>\n
\n 17,237<\/span><\/p>\n<\/td>\n
<\/td>\n \n 118,110<\/span><\/p>\n<\/td>\n
\n 16,635<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Goodwill<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 162,574<\/span><\/p>\n<\/td>\n
\n 23,571<\/span><\/p>\n<\/td>\n
<\/td>\n \n –<\/span><\/p>\n<\/td>\n
\n –<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Investments accounted for using the <\/b><\/span><\/p>\n
equity method<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 30,850<\/span><\/p>\n<\/td>\n
\n 4,473<\/span><\/p>\n<\/td>\n
<\/td>\n \n 12,082<\/span><\/p>\n<\/td>\n
\n 1,702<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Other non-current assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 10,911<\/span><\/p>\n<\/td>\n
\n 1,582<\/span><\/p>\n<\/td>\n
<\/td>\n \n 4,282<\/span><\/p>\n<\/td>\n
\n 603<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Total assets<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 4,073,665<\/b><\/span><\/p>\n<\/td>\n
\n 590,625<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 2,612,967<\/b><\/span><\/p>\n<\/td>\n
\n 368,028<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n \n Liabilities and shareholders’ equity<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n \n Current liabilities<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n \n Short-term bank borrowings<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 18,956<\/span><\/p>\n<\/td>\n
\n 2,748<\/span><\/p>\n<\/td>\n
<\/td>\n \n 29,970<\/span><\/p>\n<\/td>\n
\n 4,221<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Accruals and other payables<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 706,572<\/span><\/p>\n<\/td>\n
\n 102,443<\/span><\/p>\n<\/td>\n
<\/td>\n \n 357,754<\/span><\/p>\n<\/td>\n
\n 50,389<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Operating lease liabilities, current<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 23,961<\/span><\/p>\n<\/td>\n
\n 3,474<\/span><\/p>\n<\/td>\n
<\/td>\n \n 21,890<\/span><\/p>\n<\/td>\n
\n 3,083<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Contract liabilities, current<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 8,677<\/span><\/p>\n<\/td>\n
\n 1,258<\/span><\/p>\n<\/td>\n
<\/td>\n \n 2,200<\/span><\/p>\n<\/td>\n
\n 310<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Total current liabilities<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 758,166<\/b><\/span><\/p>\n<\/td>\n
\n 109,923<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 411,814<\/b><\/span><\/p>\n<\/td>\n
\n 58,003<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Put right liabilities<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 88,687<\/span><\/p>\n<\/td>\n
\n 12,858<\/span><\/p>\n<\/td>\n
<\/td>\n \n 98,110<\/span><\/p>\n<\/td>\n
\n 13,819<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Contract liabilities, non-current<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 267,878<\/span><\/p>\n<\/td>\n
\n 38,839<\/span><\/p>\n<\/td>\n
<\/td>\n \n 292,124<\/span><\/p>\n<\/td>\n
\n 41,145<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Operating lease liabilities, non-<\/b><\/span><\/p>\n
current<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 32,069<\/span><\/p>\n<\/td>\n
\n 4,650<\/span><\/p>\n<\/td>\n
<\/td>\n \n 23,099<\/span><\/p>\n<\/td>\n
\n 3,253<\/span><\/p>\n<\/td>\n<\/tr>\n
\n \n Other non-current liabilities<\/b><\/span><\/p>\n<\/td>\n
<\/td>\n \n 16,963<\/span><\/p>\n<\/td>\n
\n 2,459<\/span><\/p>\n<\/td>\n
<\/td>\n \n 69,664<\/span><\/p>\n<\/td>\n
\n 9,811<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
- Top-line Phase 1 dose escalation and dose expansion results are expected to be presented at a major medical conference in the first half of 2024.<\/li>\n<\/ul>\n
- The enrollment of patients from the U.S. and China<\/span> with newly diagnosed (frontline treatment) gastric and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor began in the first quarter of 2024.<\/li>\n<\/ul>\n
- Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors for patients with newly diagnosed NSCLC in 1H 2024<\/i><\/li>\n